HC Wainwright & Co. Reiterates Lumos Pharma (LUMO) Buy Recommendation
Fintel reports that on September 6, 2023, HC Wainwright & Co. reiterated coverage of Lumos Pharma (NASDAQ:LUMO) with a Buy recommendation.
Analyst Price Forecast Suggests 509.59% Upside
As of August 31, 2023, the average one-year price target for Lumos Pharma is 20.60. The forecasts range from a low of 10.10 to a high of $29.40. The average price target represents an increase of 509.59% from its latest reported closing price of 3.38.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Lumos Pharma is 0MM, a decrease of 78.13%. The projected annual non-GAAP EPS is -3.80.
What is the Fund Sentiment?
There are 53 funds or institutions reporting positions in Lumos Pharma. This is a decrease of 4 owner(s) or 7.02% in the last quarter. Average portfolio weight of all funds dedicated to LUMO is 0.01%, an increase of 99.63%. Total shares owned by institutions increased in the last three months by 6.88% to 2,474K shares.